Ourfinancial model forecasts sustained profitability in 2011

In addition, theanalysts at Zacks Equity Research discuss the latest on Johnson & Johnson (NYSE:JNJ), Exxon-Mobil (NYSE: XOM) and iPass Inc (Nasdaq: IPAS). Full analysis of all these stocks is available at: of the DayIsis Pharmaceuticals, Inc. The companys leading candidates are mipomersen for high cholesterol andISIS-113715 for diabetes, along with several other proprietary and partneredprograms for oncology, inflammatory disease, asthma, and viral infections. Ourfinancial model forecasts sustained profitability in 2011.

We are reiterating or rating on Isis Pharmaceuticals of a Buy and maintainingour price target of $22. Thecompany designs and develops educational products, as well as relatedinteractive software and content, under multiple product platforms, includingthe LeapFrog, LeapPad, Leapster, and Quantum Leap brands. Management's actions to improve long-term operating results through increasedR&D and incremental marketing spending resulted in another year of negativeearnings in 2007. is negatively impacting spending ondiscretionary products and is currently a headwind for the company's progress.Therefore, the stock is rated a Sell. Recent Analysis from the Analyst BlogIndexes Point to BleaknessThere is nothing in this report that would cause the market to be up the waythat it is today That may, after all, be the best news there is.

The market hasstarted to ignore all bad news, which is often a healthy development. On the other hand, it could just mean that the market is being overlyoptimistic. CNBC came out with a survey this morning of money managers, and 26of them expect the market to be up over 20 in 2009, while only 6 expect themarket to be down in 2009. This is EXTREMELY disturbing news, as an overwhelmingconsensus of money managers is almost ALWAYS WRONG. The economy is going to be very ugly in 2009, and I would advise sticking tofirms with products that people need, not want, and which have fortress balancesheets. A solid dividend yield that is well covered, even by the low estimate of2009 earnings, is also a plus.